- Home
- WNEB vs STTK Comparison
WNEB vs STTK Comparison
Compare WNEB & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WNEB
- STTK
- Stock Information
- Founded
- WNEB 1853
- STTK 2016
- Country
- WNEB United States
- STTK United States
- Employees
- WNEB N/A
- STTK N/A
- Industry
- WNEB Savings Institutions
- STTK Biotechnology: Pharmaceutical Preparations
- Sector
- WNEB Finance
- STTK Health Care
- Exchange
- WNEB Nasdaq
- STTK Nasdaq
- Market Cap
- WNEB 165.5M
- STTK 173.6M
- IPO Year
- WNEB N/A
- STTK 2020
- Fundamental
- Price
- WNEB $8.74
- STTK $3.69
- Analyst Decision
- WNEB Hold
- STTK Strong Buy
- Analyst Count
- WNEB 4
- STTK 3
- Target Price
- WNEB $8.50
- STTK $10.67
- AVG Volume (30 Days)
- WNEB 38.8K
- STTK 122.7K
- Earning Date
- WNEB 10-22-2024
- STTK 11-07-2024
- Dividend Yield
- WNEB 3.18%
- STTK N/A
- EPS Growth
- WNEB N/A
- STTK N/A
- EPS
- WNEB 0.63
- STTK N/A
- Revenue
- WNEB $74,435,000.00
- STTK $4,123,999.00
- Revenue This Year
- WNEB N/A
- STTK $164.45
- Revenue Next Year
- WNEB $5.16
- STTK N/A
- P/E Ratio
- WNEB $13.77
- STTK N/A
- Revenue Growth
- WNEB N/A
- STTK 380.09
- 52 Week Low
- WNEB $6.00
- STTK $1.33
- 52 Week High
- WNEB $9.25
- STTK $11.76
- Technical
- Relative Strength Index (RSI)
- WNEB 62.55
- STTK 51.49
- Support Level
- WNEB $8.45
- STTK $3.63
- Resistance Level
- WNEB $8.90
- STTK $3.94
- Average True Range (ATR)
- WNEB 0.19
- STTK 0.23
- MACD
- WNEB -0.04
- STTK 0.06
- Stochastic Oscillator
- WNEB 53.70
- STTK 56.14
About WNEB Western New England Bancorp Inc.
Western New England Bancorp Inc through its bank subsidiary, provides a range of financial services to individuals and companies in western Massachusetts and northern Connecticut. These services include commercial lending, residential lending and consumer lending, checking, savings and time deposits, cash management, and wealth management. Substantially all of the Company's revenues, profits, and assets are derived by the Bank from banking products and services.
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.